QuVa Pharma, Inc. has voluntarily recalled 21 different pain management medications, including various formulations of fentanyl, bupivacaine, and ropivacaine, because they may contain microscopic glass fragments. The issue was triggered by a recall from the raw material manufacturer of the fentanyl API used to compound these drugs. These prescription medications are typically administered by healthcare professionals in hospital or surgical settings, and the affected products were distributed nationwide.
Injecting a medication that contains glass particles can cause serious health complications, such as inflammation or damage to blood vessels, granulomas (clumps of immune cells), or life-threatening blood clots that can travel to the lungs or brain. While no injuries have been reported to date, the presence of particulate matter in sterile injectable drugs poses a medium-level safety risk.
Healthcare provider notification and product return.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.